COMPARATIVE ANALYSIS OF IMPACT OF TUMOUR ANTIGEN PREPARATION METHODS ON HUMAN DENDRITIC CELLS PRIMING AND EFFICIENT CYTOKINE-INDUCED KILLER CELLS ACTIVATION IN VITRO
DOI:
https://doi.org/10.26577/10.26577/eb.2021.v86.i1.08Abstract
Adaptive cell immunotherapy namely combination of dendritic cells (DC) and cytokine-induced killer (CIK) cells is a promising tool in treating various types of cancer and choosing the appropriate technique of tumour antigens obtaining is a challenging issue. CIK cells also called NKT cells are an in vitro propagated population of cells characterized by hybrid NK cells and T cells phenotype. DCs are highly specialized antigen-presenting cells, which uptake, process and present antigens to effector cells of the immune system. In this study, we compared the effect of tumour antigens obtained by different methods on dendritic cells maturation and their ability to activate CIK cells. Cytotoxicity of CIK cells, generated in two different conditions (whole blood or peripheral blood mononuclear cells), was accessed using SW620 cells as a target by MTT assay. According to obtained results, CIK cells expanded from whole blood showed significantly strong anti-tumoral activity compared to CIK cells generated from peripheral blood mononuclear cells isolated by Histopaque-1077 density gradient centrifugation. Also, we determined that all examined methods of antigen preparation can be used, but only in the case of antigen-loaded DCs cocultivation with CIK cells.
Key words: Сytokine-induced killer cell, dendritic cell, immunogenic cell death, damage-associated molecular pattern, TNF-alpha.
References
1. Bray F, Ferlay J, Soerjomataram I, et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
2. Ruella M, Kalos M (2014) Adoptive immunotherapy for cancer. Immunol Rev 257:14–38. https://doi.org/10.1111/imr.12136
3. Steinman RM, Cohn ZA (1973) Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 137:1142–1162. https://doi.org/10.1084/jem.137.5.1142
4. Inaba K, Metlay JP, Crowley MT, et al (1990) Dendritic cells as antigen presenting cells in vivo. Int Rev Immunol 6:197–206. https://doi.org/10.3109/08830189009056630
5. de Winde CM, Munday C, Acton SE (2020) Molecular mechanisms of dendritic cell migration in immunity and cancer. Med Microbiol Immunol (Berl) 209:515–529. https://doi.org/10.1007/s00430-020-00680-4
6. Schmidt-Wolf IG, Negrin RS, Kiem HP, et al (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174:139–149. https://doi.org/10.1084/jem.174.1.139
7. Sangiolo D (2011) Cytokine Induced Killer Cells as Promising Immunotherapy for Solid Tumors. J Cancer 2:363–368
8. Iudicone P, Fioravanti D, Cicchetti E, et al (2016) Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway. Hum Immunol 77:1239–1247. https://doi.org/10.1016/j.humimm.2016.09.003
9. Bremm M, Pfeffermann L-M, Cappel C, et al (2019) Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells. Front Immunol 10:. https://doi.org/10.3389/fimmu.2019.01218
10. Heinze A, Grebe B, Bremm M, et al (2019) The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their ex vivo Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation. Front Immunol 10:. https://doi.org/10.3389/fimmu.2019.02816
11. Pan Q-Z, Liu Q, Zhou Y-Q, et al (2020) CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma. Cancer Immunol Immunother 69:825–834. https://doi.org/10.1007/s00262-020-02486-y
12. Yang L, Ren B, Li H, et al (2013) Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 62:65–73. https://doi.org/10.1007/s00262-012-1311-8
13. Qu H-Q, Zhou X-S, Zhou X-L, Wang J (2014) Effect of DC-CIK cell on the proliferation, apoptosis and differentiation of leukemia cells. Asian Pac J Trop Med 7:659–662. https://doi.org/10.1016/S1995-7645(14)60111-5
14. Obeid M, Tesniere A, Ghiringhelli F, et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54–61. https://doi.org/10.1038/nm1523
15. Radogna F, Diederich M (2018) Stress-induced cellular responses in immunogenic cell death: Implications for cancer immunotherapy. Biochem Pharmacol 153:12–23. https://doi.org/10.1016/j.bcp.2018.02.006
16. Strome SE, Voss S, Wilcox R, et al (2002) Strategies for Antigen Loading of Dendritic Cells to Enhance the Antitumor Immune Response. Cancer Res 62:1884–1889
17. Kornacker M, Moldenhauer G, Herbst M, et al (2006) Cytokine-induced killer cells against autologous CLL: Direct cytotoxic effects and induction of immune accessory molecules by interferon-γ. Int J Cancer 119:1377–1382. https://doi.org/10.1002/ijc.21994
18. Liu Y, Liu H, Liu H, et al (2016) Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old. Oncol Lett 12:5205–5210. https://doi.org/10.3892/ol.2016.5337
19. Nishimura R, Baker J, Beilhack A, et al (2008) In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 112:2563–2574. https://doi.org/10.1182/blood-2007-06-092817
20. Rettinger E, KuçI S, Naumann I, et al (2012) The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy 14:91–103. https://doi.org/10.3109/14653249.2011.613931
21. Jafari S, Lavasanifar A, Hejazi MS, et al (2020) STAT3 inhibitory stattic enhances immunogenic cell death induced by chemotherapy in cancer cells. DARU J Pharm Sci 28:159–169. https://doi.org/10.1007/s40199-020-00326-z
22. Gu J, Li Z, Zhou J, et al (2019) Response prediction to oxaliplatin plus 5‑fluorouracil chemotherapy in patients with colorectal cancer using a four‑protein immunohistochemical model. Oncol Lett 18:2091–2101. https://doi.org/10.3892/ol.2019.10474
23. Inoue H, Tani K (2014) Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ 21:39–49. https://doi.org/10.1038/cdd.2013.84
24. Liu P, Zhao L, Loos F, et al (2017) Identification of pharmacological agents that induce HMGB1 release. Sci Rep 7:14915. https://doi.org/10.1038/s41598-017-14848-1
25. Dubyak GR (2019) Luciferase-assisted detection of extracellular ATP and ATP metabolites during immunogenic death of cancer cells. Methods Enzymol 629:81–102. https://doi.org/10.1016/bs.mie.2019.10.006
26. Yoon S, Park SJ, Han JH, et al (2014) Caspase-dependent cell death-associated release of nucleosome and damage-associated molecular patterns. Cell Death Dis 5:e1494–e1494. https://doi.org/10.1038/cddis.2014.450
27. Li C, Sun H, Wei W, et al (2020) Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression. Cell Oncol. https://doi.org/10.1007/s13402-020-00544-2
28. Bezu L, Sauvat A, Humeau J, et al (2018) eIF2α phosphorylation is pathognomonic for immunogenic cell death. Cell Death Differ 25:1375–1393. https://doi.org/10.1038/s41418-017-0044-9
29. López MN, Pereda C, Segal G, et al (2009) Prolonged Survival of Dendritic Cell–Vaccinated Melanoma Patients Correlates With Tumor-Specific Delayed Type IV Hypersensitivity Response and Reduction of Tumor Growth Factor β-Expressing T Cells. J Clin Oncol 27:945–952. https://doi.org/10.1200/JCO.2008.18.0794
30. Rojas-Sepúlveda D, Tittarelli A, Gleisner MA, et al (2018) Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer. Cancer Immunol Immunother 67:1897–1910. https://doi.org/10.1007/s00262-018-2157-5
2. Ruella M, Kalos M (2014) Adoptive immunotherapy for cancer. Immunol Rev 257:14–38. https://doi.org/10.1111/imr.12136
3. Steinman RM, Cohn ZA (1973) Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 137:1142–1162. https://doi.org/10.1084/jem.137.5.1142
4. Inaba K, Metlay JP, Crowley MT, et al (1990) Dendritic cells as antigen presenting cells in vivo. Int Rev Immunol 6:197–206. https://doi.org/10.3109/08830189009056630
5. de Winde CM, Munday C, Acton SE (2020) Molecular mechanisms of dendritic cell migration in immunity and cancer. Med Microbiol Immunol (Berl) 209:515–529. https://doi.org/10.1007/s00430-020-00680-4
6. Schmidt-Wolf IG, Negrin RS, Kiem HP, et al (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174:139–149. https://doi.org/10.1084/jem.174.1.139
7. Sangiolo D (2011) Cytokine Induced Killer Cells as Promising Immunotherapy for Solid Tumors. J Cancer 2:363–368
8. Iudicone P, Fioravanti D, Cicchetti E, et al (2016) Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway. Hum Immunol 77:1239–1247. https://doi.org/10.1016/j.humimm.2016.09.003
9. Bremm M, Pfeffermann L-M, Cappel C, et al (2019) Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells. Front Immunol 10:. https://doi.org/10.3389/fimmu.2019.01218
10. Heinze A, Grebe B, Bremm M, et al (2019) The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their ex vivo Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation. Front Immunol 10:. https://doi.org/10.3389/fimmu.2019.02816
11. Pan Q-Z, Liu Q, Zhou Y-Q, et al (2020) CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma. Cancer Immunol Immunother 69:825–834. https://doi.org/10.1007/s00262-020-02486-y
12. Yang L, Ren B, Li H, et al (2013) Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 62:65–73. https://doi.org/10.1007/s00262-012-1311-8
13. Qu H-Q, Zhou X-S, Zhou X-L, Wang J (2014) Effect of DC-CIK cell on the proliferation, apoptosis and differentiation of leukemia cells. Asian Pac J Trop Med 7:659–662. https://doi.org/10.1016/S1995-7645(14)60111-5
14. Obeid M, Tesniere A, Ghiringhelli F, et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54–61. https://doi.org/10.1038/nm1523
15. Radogna F, Diederich M (2018) Stress-induced cellular responses in immunogenic cell death: Implications for cancer immunotherapy. Biochem Pharmacol 153:12–23. https://doi.org/10.1016/j.bcp.2018.02.006
16. Strome SE, Voss S, Wilcox R, et al (2002) Strategies for Antigen Loading of Dendritic Cells to Enhance the Antitumor Immune Response. Cancer Res 62:1884–1889
17. Kornacker M, Moldenhauer G, Herbst M, et al (2006) Cytokine-induced killer cells against autologous CLL: Direct cytotoxic effects and induction of immune accessory molecules by interferon-γ. Int J Cancer 119:1377–1382. https://doi.org/10.1002/ijc.21994
18. Liu Y, Liu H, Liu H, et al (2016) Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old. Oncol Lett 12:5205–5210. https://doi.org/10.3892/ol.2016.5337
19. Nishimura R, Baker J, Beilhack A, et al (2008) In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 112:2563–2574. https://doi.org/10.1182/blood-2007-06-092817
20. Rettinger E, KuçI S, Naumann I, et al (2012) The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy 14:91–103. https://doi.org/10.3109/14653249.2011.613931
21. Jafari S, Lavasanifar A, Hejazi MS, et al (2020) STAT3 inhibitory stattic enhances immunogenic cell death induced by chemotherapy in cancer cells. DARU J Pharm Sci 28:159–169. https://doi.org/10.1007/s40199-020-00326-z
22. Gu J, Li Z, Zhou J, et al (2019) Response prediction to oxaliplatin plus 5‑fluorouracil chemotherapy in patients with colorectal cancer using a four‑protein immunohistochemical model. Oncol Lett 18:2091–2101. https://doi.org/10.3892/ol.2019.10474
23. Inoue H, Tani K (2014) Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ 21:39–49. https://doi.org/10.1038/cdd.2013.84
24. Liu P, Zhao L, Loos F, et al (2017) Identification of pharmacological agents that induce HMGB1 release. Sci Rep 7:14915. https://doi.org/10.1038/s41598-017-14848-1
25. Dubyak GR (2019) Luciferase-assisted detection of extracellular ATP and ATP metabolites during immunogenic death of cancer cells. Methods Enzymol 629:81–102. https://doi.org/10.1016/bs.mie.2019.10.006
26. Yoon S, Park SJ, Han JH, et al (2014) Caspase-dependent cell death-associated release of nucleosome and damage-associated molecular patterns. Cell Death Dis 5:e1494–e1494. https://doi.org/10.1038/cddis.2014.450
27. Li C, Sun H, Wei W, et al (2020) Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression. Cell Oncol. https://doi.org/10.1007/s13402-020-00544-2
28. Bezu L, Sauvat A, Humeau J, et al (2018) eIF2α phosphorylation is pathognomonic for immunogenic cell death. Cell Death Differ 25:1375–1393. https://doi.org/10.1038/s41418-017-0044-9
29. López MN, Pereda C, Segal G, et al (2009) Prolonged Survival of Dendritic Cell–Vaccinated Melanoma Patients Correlates With Tumor-Specific Delayed Type IV Hypersensitivity Response and Reduction of Tumor Growth Factor β-Expressing T Cells. J Clin Oncol 27:945–952. https://doi.org/10.1200/JCO.2008.18.0794
30. Rojas-Sepúlveda D, Tittarelli A, Gleisner MA, et al (2018) Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer. Cancer Immunol Immunother 67:1897–1910. https://doi.org/10.1007/s00262-018-2157-5
Downloads
How to Cite
Zhunussova, M. S., Issabekova, A. S., & Ogay, V. B. (2021). COMPARATIVE ANALYSIS OF IMPACT OF TUMOUR ANTIGEN PREPARATION METHODS ON HUMAN DENDRITIC CELLS PRIMING AND EFFICIENT CYTOKINE-INDUCED KILLER CELLS ACTIVATION IN VITRO. Experimental Biology, 86(1), 90–97. https://doi.org/10.26577/10.26577/eb.2021.v86.i1.08
Issue
Section
МOLECULAR BIOLOGY AND GENETICS
